CAH
Cardinal Health, Inc.
CAH has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over CAH overall, supported by stronger fundamentals and stronger valuation.
CAH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Healthy |
CAH's profitability and balance sheet are currently healthy, and its revenue and cash flow are stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CAH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 17x | $130 | -53% |
| Forward | 21x | $278 | — |
| Fair | 30x | $231 | -17% |
| Current | 36x | $278 | — |
| Expensive | 44x | $341 | +23% |
Historical ranges are pointers, not guarantees.
CAH's PE is in its expensive range at 36x. If earnings grow as analysts expect, today's price would be 21x next year's earnings, in its cheap range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over CAH in the historical PE scenario, which offers more potential upside but is not a forecast.
CAH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Stable | |
| Limited | |
| Moderate |
Analysts expect CAH's earnings to grow, with its revenue and profitability holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over CAH on the outlook, with more favorable revenue and profitability expectations.
CAH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.12 | +70% |
| Q3 2026 | $7.73 | +17% |
| Q2 2026 | $7.23 | +12% |
| Q1 2026 | $6.54 | +2.5% |
| Q4 2025 | $6.95 | +30% |
| Q3 2025 | $6.63 | +30% |
| Q2 2025 | $6.45 | +88% |
| Q1 2025 | $6.38 | +182% |
| Q4 2024 | $5.33 | +109% |
CAH has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
CAH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $67.5B | +5.5% |
| Q2 2026 | $63.7B | +5.8% |
| Q1 2026 | $60.9B | +11% |
| Q4 2025 | $65.6B | +19% |
| Q3 2025 | $64B | +22% |
| Q2 2025 | $60.2B | +0.8% |
| Q1 2025 | $54.9B | -0.1% |
| Q4 2024 | $55.3B | -3.8% |
CAH's revenue has grown year over year for six quarters in a row: $67.5B last quarter, up 5.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.1% | +0.1 points |
| Q2 2026 | 1.1% | +0.4 points |
| Q1 2026 | 0.8% | -0.5 points |
| Q4 2025 | 1.1% | +0.1 points |
| Q3 2025 | 1% | -0.1 points |
| Q2 2025 | 0.7% | 0 points |
| Q1 2025 | 1.3% | +0.7 points |
| Q4 2024 | 1% | +0.2 points |
CAH's operating margin was 1.1% last quarter, about level with the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CAH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over CAH on profitability, with a higher operating margin.
CAH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.2B | +43% |
| Q2 2026 | $1.4B | +10% |
| Q1 2026 | $1.7B | -40% |
| Q4 2025 | $555M | +$1.1B |
| Q3 2025 | $865M | +$2.6B |
| Q2 2025 | $1.3B | -31% |
| Q1 2025 | $2.8B | +$3B |
| Q4 2024 | -$499M | -146% |
CAH generated $4.9B in free cash flow over the past year, up 10% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CAH on cash flow, with more consistent year-over-year improvement.
CAH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.7% | -4M shares |
| 1 year | -2.5% | -6M shares |
| 3 years | -6.8% | -17M shares |
| 5 years | -19% | -56M shares |
| Available history | -21% | -61M shares |
CAH has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $500M |
| Q2 2026 | $350M |
| Q1 2026 | $250M |
| Q4 2025 | $383M |
| Q3 2025 | $375M |
| Q2 2025 | — |
| Q1 2025 | $375M |
| Q4 2024 | $15M |
CAH spent $1.5B buying back its own shares over the past year, up 94% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CAH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.0x | Very low |
| Q2 2026 | 1.1x | Healthy |
| Q1 2026 | 1.5x | Healthy |
| Q4 2025 | 1.8x | Healthy |
| Q3 2025 | 1.4x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.4x | Healthy |
| Q4 2024 | 1.4x | Healthy |
CAH's net debt is about a year of its operating earnings (EBITDA), down from 1.4 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over CAH on leverage, with a lower net debt burden relative to earnings.
CAH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 70.8 | Overbought |
| Stochastic | 81.9 | Overbought |
CAH's weekly RSI is 71 (overbought) and its Stochastic is 82 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CAH PE vs Healthcare Sector
| Metric | CAH | Sector median | Relative |
|---|---|---|---|
| PE | 36x | 26x | 39% above |
| PE % | 73 | 29 | 44 pts above |
CAH is trading at 36x earnings, a 39% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over CAH on valuation relative to its sector.
CAH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $248.8 | 12% above |
| 20 week MA | $239.7 | 16% above |
| 50 week MA | $222.0 | 25% above |
| 100 week MA | $185.9 | 50% above |
| 200 week MA | $141.9 | 96% above |
CAH is in an uptrend: it's above all five of its weekly moving averages, and 96% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
CAH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.5 | $53.8 | +4.5% |
| 2021 | $53.8 | $50.8 | -5.7% |
| 2022 | $50.8 | $80.1 | +58% |
| 2023 | $80.1 | $100.8 | +26% |
| 2024 | $100.8 | $119.1 | +18% |
| 2025 | $119.1 | $208.3 | +75% |
| 2026 YTD | $208.3 | $278.1 | +34% |
CAH has finished higher in five of the last six years, two of them by more than 50%. It's up 34% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CAH on returns for 2026, with the stronger performance.